Whistleblower due $266.4M in Biogen drug kickback settlement

The whistleblower’s $266 million share of Biogen’s $900 million settlement to resolve allegations that the company paid kickbacks to physicians to induce them to prescribe the company’s multiple sclerosis drugs is the largest whistleblower award in US history.